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Abstract
Aims/hypothesis Early-onset type 2 diabetes is associated
with marked visceral obesity and extreme insulin resistance,
but its pathogenesis and response to treatment are not
completely understood. We studied physical fitness, whole-
body and hepatic glucose turnover, and insulin secretion in
young obese Irish subjects before and after 3 months of
aerobic exercise training. We hypothesised that exercise
alone, with stable diet, should improve insulin sensitivity.
Materials and methods Anthropometric parameters and
maximum volume of oxygen utilisation (VO2max) were
measured in 13 subjects with type 2 diabetes and 18 non-
diabetic control subjects, matched for age and BMI. Insulin
sensitivity and hepatic glucose turnover were measured
using the hyperinsulinaemic–euglycaemic clamp. Insulin
secretion was assessed from an OGTT and a modified
intravenous glucose tolerance test. Some subjects (seven type 2
diabetic, 14 non-diabetic control subjects) then completed a
12-week supervised aerobic exercise programme. All mea-
surements were repeated on completion of the exercise
programme.
Results Type 2 diabetic subjects had higher WHR, systolic
blood pressure and triacylglycerols than non-diabetic
control subjects. They were significantly more insulin-
resistant as measured both by the clamp and oral glucose
insulin sensitivity. They also displayed marked defects in
insulin secretion in response to oral and intravenous
glucose challenges. Exercise intervention had no significant
effect on whole-body or hepatic insulin sensitivity or
insulin secretion. VO2max increased significantly in the
non-diabetic control subjects, but not in the type 2 diabetic
subjects after exercise training.
Conclusions/interpretation Young obese subjects with type 2
diabetes are severely insulin-resistant with marked loss of
beta cell function compared with control subjects matched
for age and obesity. Neither group responded metabolically
to aerobic exercise intervention.
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Marked visceral obesity and extreme insulin resistance are
associated with early-onset type 2 diabetes. The prevalence
of diabetes is predicted to more than double to 366 million by
2030 [1]. A more recent trend has been the shift of type 2
diabetes to middle-aged and younger populations. The new
epidemic of obesity and type 2 diabetes in young people is
becoming a clinical and health economic priority [2].
In Ireland, in the last decade, the prevalence of obesity
has increased by 67% [3]. Irish adolescent boys and girls
ranked third and second highest respectively in an
international study of obesity prevalence rates [4]. This
has been associated with significant changes in physical
activity and diet in this age group [5]. However, the exact
sequence of events leading to type 2 diabetes in youth is not
fully understood. We have reported that younger Irish
adults (aged less than 40 years) with type 2 diabetes are
more obese, more dyslipidaemic and have worse initial and
ongoing glycaemic control than older adults with type 2
diabetes in spite of similar treatment protocols [6]. In a
separate study of younger white Irish subjects with type 2
diabetes (mean age 22 years), we used an insulin-modified
intravenous glucose tolerance test (IVGTT) to demonstrate
severe insulin resistance and loss of first-phase insulin
secretion [7]. This cohort had evidence of high risk for
cardiovascular complications, with elevated markers of
endothelial dysfunction. This suggests that a disproportion-
ate cardiovascular risk burden is associated with type 2
diabetes in younger patients. To date there have been no
studies of insulin sensitivity using the hyperinsulinaemic–
euglycaemic clamp technique in this population.
There is considerable evidence that exercise delays or
prevents the development of type 2 diabetes in at-risk
populations [8–12]. Smaller studies have shown that
exercise improves insulin sensitivity and glucose metabo-
lism [13, 14]. We have recently shown that short-term
exercise training increased insulin sensitivity by more than
50% in obese middle-aged patients (mean age 45 years)
with type 2 diabetes [15]. In these patients the main
biochemical change was an increase in glucose transporter 4
(GLUT4) protein content in skeletal muscle. These
improvements, while impressive, are likely to be propor-
tional to the duration and intensity of the exercise regime
[16]. The metabolic benefits of exercise are known to be
short-lived [17–20]. This has important implications for the
design and optimisation of exercise interventions.
The aim of the current study was to examine the effects
of a 3-month aerobic exercise training programme in young
obese insulin-resistant subjects with and without type 2
diabetes. We hypothesised that exercise would lead to an
improvement in insulin sensitivity in these severely insulin-
resistant subjects. We used the glucose clamp and tracer
techniques to measure the effects of exercise on whole-
body and hepatic insulin sensitivity and insulin secretion.
Subjects and methods
Study population
Patients aged between 15 and 30 years, who were attending
either the endocrinology or diabetes services at St James’
Hospital, Dublin and had obesity or type 2 diabetes, were
invited to take part in the study. Subjects with co-existing
illnesses or secondary forms of diabetes were excluded. The
study protocol was approved by the local Research Ethics
Committee and written informed consent was obtained.
Screening
Subjects attended the Metabolic Research Unit on one
morning at 08.00 h for documentation of their full history
and a physical examination. Routine blood samples were
taken for blood count, renal, liver, bone profile, thyroid
function tests and fasting lipids. Each subject with diabetes
was confirmed negative for GAD antibodies.
Anthropometric measurements
Waist-to-hip ratio, weight, height and BMI were measured.
Blood pressure was measured using the left arm after the
subject had been sitting comfortably for 5 min, using an
oscillometric device (Omron 705 CP; Omron, Matsusaka,
Japan). Three readingswere taken and the lowest one recorded.
Body composition was assessed using an electrical impedance
device (Tanita TBF-300 Body Composition Analyser; Tanita,
Tokyo, Japan). Urinalysis and 12-lead ECG were performed.
Testing of maximum volume of oxygen utilisation
Maximum volume of oxygen utilisation (VO2max) was mea-
sured using a bicycle ergometer (Excalibur, Groningen, the
Netherlands) in a stepwise fashion. Heart rate and oxygen
consumption were recorded. Blood pressure was monitored.
OGTT
An OGTT (75 g glucose load) was performed. Insulin and
C- peptide levels were measured in addition to blood
glucose, at 30-min intervals over 2 h.
Hyperinsulinaemic–euglycaemic clamp study
On a separate morning (within 7 days of the OGTT),
subjects attended the unit for a 4-h hyperinsulinaemic–
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euglycaemic clamp study. Subjects fasted for 12 h prior to
the clamp. Diabetic subjects taking insulin omitted the
basal dose on the night before the clamp as well as the
dose on the morning of the clamp study. Subjects taking
metformin stopped this 1 week before the study, while
subjects taking sulfonylureas stopped these 3 days before
the clamp. During a 2-h basal phase, [6,6-2H2]glucose
tracer (Cambridge Isotopes, Cambridge, MA, USA) was
infused through an intravenous cannula in the right
antecubital fossa. Subsequently a 2-h insulin infusion
(Actrapid; Novo Nordisk, Bagsvaerd, Denmark) was
commenced through an intravenous cannula in the left
antecubital fossa at a rate of 40 mU m−2 min−1.
Simultaneously a [6,6-2H2]glucose solution was infused
in order to maintain euglycaemia. To monitor blood
glucose levels during the clamp study, arterialised venous
blood was taken at 5-min intervals from a retrograde
cannula on the dorsum of the right hand, which was
warmed. The mean glucose infusion rate between 80 and
120 min after commencement of the insulin infusion was
calculated. The glucose disposal rate was calculated after
correction for residual hepatic glucose production using
the [6,6-2H2]glucose tracer [21–23].
Modified intravenous glucose tolerance test
At the end of the clamp study (at 240 min), a rapid bolus of
intravenous glucose was administered (0.3 g/kg) over 20 s and
serial blood samples taken every 2 min for 8 min to measure
insulin, C-peptide and glucose. The IVGTT has been used in
similar cohorts to assess beta cell function in the past [7].
Analysis methods for OGTT and IVGTT data
Beta cell function was assessed using a model that
describes the relationship between insulin secretion and
glucose concentration and that has been illustrated in detail
previously [24, 25]. The model expresses insulin secretion
as a sum of two components. The first component
represents the dependence of insulin secretion on absolute
glucose concentration at any time point and is characterised
by a dose–response function relating the two variables. The
characteristic parameter of the dose–response is the mean
slope within the observed glucose range, denoted as ‘beta
cell glucose sensitivity.’ The dose–response is modulated
by a potentiation factor, which accounts for several
potentiating factors (prolonged exposure to hyperglycae-
mia, non-glucose substrates, gastrointestinal hormones and
neurotransmitters). The potentiation factor is set to be a
positive function of time and to average 1 during the
experiment. It thus expresses a relative potentiation of the
secretory response to glucose. Previous studies [24–26]
have found that insulin secretion at the end of an OGTT or
meal is relatively higher than at the beginning for comparable
glucose levels (i.e. when glucose returns to the basal level,
insulin secretion remains higher). Potentiation thus increases
during the test. This increase has been quantified as the ratio
between the potentiation factor value at 2 h after the OGTT
and that at time zero. The second insulin secretion component
represents a dynamic dependence of insulin secretion on the
rate of change of glucose concentration. This component is
termed the derivative component and is determined by a
single parameter, denoted as ‘rate sensitivity.’ Rate sensitivity
is related to early insulin release [24–26].
The model parameters were estimated from glucose and
C-peptide concentrations by regularised least-squares, as
previously described [24, 25]. Regularisation involves the
choice of smoothing factors that were selected to obtain
glucose and C-peptidemodel residuals with standard deviations
close to the expected measurement error (∼1% for glucose and
∼4% for C-peptide). Basal and total insulin secretion during the
OGTT were calculated from the estimated model parameters.
Total insulin secretion was calculated as the integral of insulin
secretion during the OGTT. Insulin secretion was expressed
in pmol min−1 m−2 of body surface area.
The acute insulin response was calculated as the mean
incremental insulin concentration during the 8-min IVGTT,
where the mean was determined by trapezoidal integration.
Analogous indices were obtained using C-peptide concen-
tration and insulin secretion, which was calculated by
deconvolution from C-peptide concentration [27].
Laboratory analysis
Serum insulin and C-peptide were measured using commer-
cially available flouroimmunoassays (Auto-Delfia, Wallac-
Oy, Finland). Plasma total cholesterol and triacylglycerols
were measured using enzymatic methods (Human liquicolor
kits; Hitachi Modular; Roche Diagnostics, Basel Switzer-
land). Plasma HDL-cholesterol and LDL-cholesterol were
measured directly with enzymatic methods (Randox direct
kits; Hitachi Modular). Plasma glucose was measured using
a glucose oxidase method (bio Merieux kit; Hitachi
Modular) and HbA1c was measured using an analyser (Hi-
Auto A1c HA 8140; Menarini, Florence Italy). Antibodies
to GAD were measured using a direct radioligand assay.
Serum NEFA were determined using a spectrophotometric
assay (Randox Laboratories, Antrim, UK).
Exercise protocol
The exercise programme was conducted entirely at the
Metabolic Research Unit gym and involved 1 h of exercise
training, four times per week for 12 weeks. Each exercise
session was supervised by an exercise physiologist or one
of the study physicians. Each subject completed a 5-min
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warm-up, followed by 60 min of aerobic exercise at 70%
VO2max (with continuous heart rate monitoring) and a 5-min
cool down either on a cycle ergometer or treadmill.
Compliance with the exercise was excellent with 95%
attendance throughout the study.
Diet
A dietitian met with each subject weekly to ensure a stable
energy intake during the study.
Statistical analysis
Data are presented as means (SEM). Comparisons between
control and young type 2 diabetes subjects at baseline
(before exercise) used a Mann–Whitney U test. Compar-
isons of both of these groups before and after exercise used
the Wilcoxon signed rank test. Statistical significance was
set at p<0.05. JMP statistical software (version 5.1; SAS
Institute, Cary, NC, USA) was used in statistical analysis.
Results
Baseline studies
Clinical and laboratory measurements We recruited 13
subjects with type 2 diabetes and 18 non-diabetic control
subjects for the baseline study. Clinical characteristics of
the subjects are shown in Table 1. The two groups were
matched for age, BMI, body fat and physical fitness. In
seven of the 13 subjects with type 2 diabetes and 11 of the
18 obese subjects there was a documented family history of
type 2 diabetes. All of the subjects had completed puberty.
Of the 13 type 2 diabetic subjects, six were receiving
metformin alone, two were receiving metformin with
sulfonylureas, three were receiving insulin (alone or in
combination with oral agents) and two were on no hypo-
glycaemic medications. No differences were subsequently
noted in the responses between these treatment sub-groups.
There was a higher proportion of men in the type 2 diabetic
subjects group, which accounted for a non-significant
difference in weight, height, body surface area and fat-free
mass. None of these differences were significant when the
sexes were analysed separately (not shown). The type 2
diabetic subjects had higher waist circumference, WHR,
fasting triacylglycerol and slightly higher systolic blood
pressure than the obese control subjects. In the subgroup (14
obese control, seven type 2 diabetic subjects) who completed
the exercise intervention, the baseline trends were similar.
Hyperinsulinaemic–euglycaemic clamp studies Basal he-
patic glucose output was increased in the type 2 diabetic
subjects (2.6±0.25 mg kg−1 min−1) compared with the
obese control subjects (1.72±0.14 mg kg−1 min−1;
p=0.0015). Glucose production was suppressed to a similar
Control (n=18) Type 2 diabetic subjects (n=13)
Male:female ratio 4:14 8:5
Mean age (years) 23.7 (0.9) 25.8 (1.2)
Weight (kg) 99.6 (4.4) 109 (5)
BMI (kg/m2) 35.2 (1.4) 34.9 (1.4)
Blood pressure (mmHg)
Systolic 114.9 (3.3) 124.9 (3.4) *
Diastolic 72.9 (2.1) 77.5 (2.5)
Waist circumference (cm) 102.1 (2.72) 117.2 (3.8) **
Hip circumference (cm) 116.4 (3.3) 115.3 (2.8)
WHR 0.88 (0.02) 1.02 (0.03) **
Body fat % 41.2 (2.15) 38.3 (3.02)
VO2max (ml min
−1 kg−1) 2.66 (0.19) 2.55 (0.2)
Fasting plasma glucose (mmol/l) 4.94 (0.34) 10.31 (0.42) ***
Total cholesterol (mmol/l) 4.42 (0.2) 4.69 (0.24)
HDL-cholesterol (mmol/l) 1.09 (0.07) 0.94 (0.04)
LDL-cholesterol (mmol/l) 2.44 (0.17) 2.67 (0.2)
Triacylglycerol (mmol/l) 1.49 (0.19) 2.9 (0.37) ***
Fasting plasma NEFA (mmol/l) 0.642 (0.041) 0.748 (0.236)
HbA1c (%) 5.39 (0.23) 8.78 (0.28) ***
Beta cell glucose sensitivity a 187.9 (44.8) 16.6 (3.3) ***
Rate sensitivity b 758.9 (165) 175.3 (60.7) *
Potentiation factor ratio 1.892 (0.44) 1.117 (0.111) *
Basal insulin secretion c 107.1 (10.5) 141.7 (13.4) *
Integral of total insulin secretion OGTT d 52.7 (6.9) 30.9 (3.6) ***
Table 1 Clinical data, lipid
profiles and metabolic data
derived from the OGTT prior
to exercise intervention: com-
parison between obese control
and obese type 2 diabetic
subjects
Values in brackets: SEM.
a pmol min−1 m−2 mmol−1 l−1
b pmol m−2 mmol−1 l−1
c pmol min−1 m−2
d nmol/m2
* p<0.05; ** p<0.01;
*** p<0.001
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degree in both groups during the clamp. Both groups were
insulin-resistant; however glucose disposal was markedly
reduced in the type 2 diabetic subjects (2.15±0.42 mg kg−1
min−1) compared with obese control subjects (4.09±
0.58 mg kg−1 min−1; p<0.03).
OGTT and IVGTT Insulin sensitivity was also calculated
from the OGTT, using oral glucose insulin sensitivity
(OGIS). The type 2 diabetic subjects were much more
insulin-resistant (OGIS 265±10 ml min−1 m−2) than obese
control subjects (OGIS 407±13 ml min−1 m−2; p<0.0001).
Beta cell function, as assessed by OGTT modelling, was
markedly impaired in type 2 diabetic subjects compared
with the control group (Table 1). Glucose sensitivity, rate
sensitivity and the potentiation factor ratio were all
significantly reduced in type 2 diabetic subjects. Glucose
sensitivity was strongly correlated with mean glucose levels
during the OGTT in the whole group (r=0.95 p<0.0001,
after log-transformation). Similar results were obtained with
2-h glucose.
In the IVGTT, the type 2 diabetic subjects subjects had
markedly reduced beta cell response to glucose. Both acute
insulin response (389±62 vs 29±71 pmol/l) and the
equivalent C-peptide measurements (997±126 vs 45±
80 pmol/l) were reduced in the type 2 diabetic subjects
subjects, as well as the incremental area of insulin secreted
after the glucose bolus (435±62 vs 19±49 pmol min−1 m−2).
Effects of exercise intervention
The exercise intervention was completed by 14 of the obese
control subjects and seven of the diabetic subjects.
Clinical and laboratory measurements Table 2 shows that
there was no change in body weight, BMI, blood pressure
or percent body fat in either group at the end of the 3-month
exercise programme. Waist circumference was reduced in
the type 2 diabetic subjects (115.2±5.5 vs 110.7±5.1 cm,
p=0.031), with a similar but not significant trend in control
subjects (100.8±3.3 vs 96.7±2.9 cm, p=0.075). VO2max
increased more than 20% in the obese control subjects
(from 2.77±0.24 to 3.36±0.41 ml min−1 kg−1 p<0.0001),
but did not improve significantly in the type 2 diabetic
subjects (2.48±0.31 to 2.72±0.35 ml min−1 kg−1, p=0.078)
(Fig. 1a). Change in VO2max in the obese group was
positively correlated with change in glucose disposal (r=
0.55, p=0.05). Mean glucose levels during the OGTT did
not change in either group after exercise. There were no
significant changes in fasting lipids. Fasting concentrations
of NEFA tended to be higher at baseline in the type 2
diabetic subjects, although this did not reach significance.
However, after completion of the exercise, NEFA were
significantly lower in the control group than in the type 2
diabetic group, in whom exercise induced no change
(Fig. 1b).
Hyperinsulinaemic–euglycaemic clamp studies Basal he-
patic glucose output was not changed in either group at the
end of the exercise intervention (Fig. 1c). Suppression of
hepatic glucose output during the clamp remained similar in
both groups and was unchanged after the exercise inter-
vention (Fig. 1d). Exercise intervention led to no significant
change in whole-body glucose disposal in either group
(4.31±0.71 vs 5.33±0.7 mg kg−1 min−1 in the control, 2.5±
0.3 vs 2.57±0.42 mg kg−1 min−1 in the type 2 diabetic
subjects, p=NS) (Fig. 1e).
OGTT and IVGTT Insulin sensitivity calculated from OGIS
did not improve in either group after exercise intervention
(417±14 vs 420±16 in the control group, p=NS; 281±16
vs 260±21 in the type 2 diabetic group, p=0.05) (Fig. 1f).
All measures of insulin secretion remained unchanged in
both groups after exercise.
Discussion
Marked visceral obesity and extreme insulin resistance are
associated with early-onset type 2 diabetes. This form of
diabetes is a growing public health problem. While visceral
obesity is an important risk factor, the natural history of this
condition in younger people is not known. Young patients
with type 2 diabetes have well established loss of beta cell
insulin secretion at the time of clinical presentation [7].
Two possibilities arise: (1) early-onset type 2 diabetes is
identical in pathogenesis and clinical course to type 2
diabetes of later onset; or (2) type 2 diabetes of early onset
is a more extreme phenotype with even greater cardiovas-
cular and lifelong risk of complications than in older
subjects. We have previously shown that patients in our
clinic with onset of diabetes under 40 years are significantly
more obese at an earlier age, have worse cardiovascular risk
profiles than their older counterparts and have worse initial
and ongoing glycaemic control, despite exactly similar care
[6]. We have also reported that young type 2 subjects have
a markedly adverse cardiovascular risk profile, as already
established in a cohort with mean age of 22 years [7]. The
clinical and research evidence to date support the hypoth-
esis that early-onset type 2 diabetes is an extreme
phenotype, distinct from the phenotype of older subjects
with typical type 2 diabetes and from that of young obese
subjects with normal glucose tolerance.
In the current study, we conducted baseline studies of
whole-body and hepatic glucose turnover using the clamp
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technique with deuterated glucose tracer. We used whole-
body VO2max as an index of physical fitness. Our subjects
were two matched groups of severely obese young subjects,
one with type 2 diabetes, the other non-diabetic. The latter
non-diabetic group was nonetheless severely insulin-resis-
tant. However, the young type 2 diabetic subjects were even
more insulin-resistant at baseline. Whole-body glucose
disposal was dramatically reduced and hepatic glucose
production was elevated under fasting conditions. During
the clamp studies, suppression of hepatic glucose produc-
tion was similar between the two groups, in contrast to
whole-body glucose disposal, which was significantly
reduced in the diabetes group. Insulin secretion was
markedly reduced in the type 2 diabetic group. The
characteristics of beta cell dysfunction in young type 2
diabetic subjects are similar to those we have observed in
older diabetic patients [26]. In particular, young type 2
diabetic subjects show the classical marked decrease in
glucose sensitivity, rate sensitivity and potentiation factor
ratio. In addition, the typical associations between mean or
2-h glucose and both beta cell glucose sensitivity and insulin
sensitivity were also observed in this group. However, the
association with glucose tolerance was stronger for beta cell
glucose sensitivity than for insulin sensitivity, suggesting
that in this insulin-resistant population the major cause of
glucose intolerance is beta cell dysfunction.
Recent studies from a group in Ohio, USA, used OGTT
and IVGTT to show that adolescents with type 2 diabetes
have significant insulin resistance, even compared with
non-diabetic subjects of similar obesity and body fatness,
and impaired insulin secretion relative to their degree of
insulin resistance [28]. In contrast to our findings, the
diabetic subjects in those studies retained a first-phase
insulin response to glucose that was comparable with lean
Table 2 Clinical data, lipid profiles and metabolic data derived from the OGTT: comparison between obese non-diabetic control and type 2
diabetes subjects pre and post exercise
Control subjects Type 2 diabetic subjects
Fixed data
n 14 7
Male : female ratio 4:10 3:4
Mean age (years) 25.6 (0.9) 26.1 (0.9)
Per exercise status Pre-exercise Post-exercise Pre-exercise Post-exercise
Weight (kg) 97.47 (4.65) 95.6 (4.54) 108.3 (8.7) 109.4 (8.4)
BMI (kg/m2) 34.25 (1.44) 33.58 (1.34) 35.63 (1.23) 36.02 (1.17)
Systolic BP (mmHg) 116.1 (4) 112.8 (4) 119 (4.7) 121 (4.2)
Diastolic BP (mmHg) 71.3 (2.4) 69.6 (2.3) 77 (2.5) 81 (2.3)
Waist circumference (cm) 100.8 (3.3) 96.7 (2.9) 115.2 (5.5) 110.7 (5.1) *
Hip circumference (cm) 113.3 (3.4) 107.1 (3) *** 116.6 (4.3) 115.3 (3.7)
WHR 0.89 (0.02) 0.9 (0.02) 0.99 (0.05) 0.96 (0.03)
Body fat % 39 (2.4) 38.4 (2.3) 39.9 (3.1) 39.7 (3.1)
VO2max (ml min
−1 kg−1) 2.77 (0.24) 3.36 (0.41) *** 2.48 (0.31) 2.72 (0.35)
Fasting plasma glucose (mmol/l) 4.97 (0.11) 4.92 (0.11) 9.39 (1.06) 10.64 (1.55)
Total cholesterol (mmol/l) 4.47 (0.26) 4.25 (0.26) 4.47 (0.3) 4.52 (0.24)
HDL-cholesterol (mmol/l) 1.12 (0.09) 1.11 (0.06) 0.96 (0.05) 0.95 (0.05)
LDL-cholesterol (mmol/l) 2.46 (0.22) 2.83 (0.25) 2.6 (0.26) 2.88 (0.18)
Triacylglycerols (mmol/l) 1.37 (0.2) 1.19 (0.13) 2.63 (0.39) 2.26 (0.29)
Fasting plasma NEFA (mmol/l) 0.635 (0.053) 0.561 (0.036) 0.820 (0.104) 0.826 (0.043)
HbA1c (%) 5.43 (0.11) 5.32 (0.16) 8.46 (0.6) 8.41 (0.73)
Beta cell glucose sensitivity a 145.19 (24.68) 128.81 (17.39) 13.29 (2.92) 21.01 (7.44)
Rate sensitivity (pmol m−2 mmol−1 l−1) 795.55 (195.44) 1095.93 (267.62) 241.38 (108.95) 196.45 (56.87)
Potentiation factor ratio 1.44 (0.14) 1.57 (0.19) 1.29 (0.18) 1.1 (0.12)
Basal insulin secretion (pmol min−1 m−2) 100.05 (12.58) 102.1 (9.53) 146.43 (15.15) 140.56 (12.42)
Integral of total insulin secretion OGTT b 43.41 (2.12) 44.13 (3.08) 29.32 (2.61) 34.31 (6.48)
Figures in brackets: SEM
a pmol min−1 m−2 mmol−1 l−1
b nmol/m2
* p<0.05; *** p<0.001
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control subjects. Another group conducted hyperinsulinae-
mic–euglycaemic clamp studies in six French subjects with
type 2 diabetes and a median age of 15.4 years [29]. Similar
to our study, they demonstrated marked insulin resistance
and beta cell failure although these subjects had very good
chronic glycaemic control.
Aerobic exercise has been shown to be effective in
improving insulin sensitivity in patients with obesity, pre-
diabetes and type 2 diabetes [13, 14, 16]. The landmark
diabetes prevention studies have proven the efficacy of
exercise intervention in preventing progression from IGT to
diabetes [9, 11, 12]. We have recently shown that just
7 days of exercise training led to increased glucose disposal
and muscle GLUT4 protein content in middle-aged, obese
subjects with type 2 diabetes (mean age 45 years, BMI
36 kg/m2) [15]. Since early-onset type 2 diabetes is
characterised by obesity and severe insulin resistance, we
chose to investigate the effect of exercise intervention in
younger subjects with type 2 diabetes. We hypothesised that
exercise alone, while maintaining a stable diet, should
improve insulin sensitivity. The advantage of the study
design was that all exercise sessions took place at our
research unit and each session was supervised by either the
exercise physiologist or study physician. The intensity of the
exercise was constantly scrutinised using continuous heart
rate monitoring. We only compared measurements in
subjects who actually completed the study (14 control and
seven type 2 diabetic subjects). To our surprise, there were
essentially no metabolic improvements in either study group
at the end of the 3-month programme. However, the obese
control group had a 20% increase in VO2max, which was
positively correlated with glucose disposal, and a reduction
in fasting NEFA when compared with the diabetic group,
despite identical compliance with the training programme.
This raises interesting new questions about the patho-
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Fig. 1 Comparison of measurements between obese non-diabetic
control and type 2 diabetes subjects at baseline and then pre-exercise
(Pre Ex) and post-exercise (Post Ex) in those who completed the
exercise programme. a VO2max; b fasting NEFA; c basal hepatic
glucose output (clamp); d steady-state hepatic glucose output (clamp);
e glucose disappearance during clamp; and f OGIS. Error bars: SEM.
YT2, young type 2 diabetic subjects. **p=0.001, #p=0.03; ##p=
0.047; ###p=0.078; †p<0.0001; ††p=0.0003
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obese young people. The duration (3 months) of exercise at
the frequency and intensity chosen for the current study
may simply have been insufficient for the improvements
that were expected. However, previous studies including
our own in equally obese but older subjects with obesity
and type 2 diabetes, have shown improvements in insulin
sensitivity and glycaemic control with similar or even less
rigorous exercise regimes [13, 14]. Another question is
whether it would have been preferable to combine the
exercise regime with a weight-losing low-energy diet.
However, subjects in the current study were instructed to
maintain a stable diet during the 3-month exercise
programme, and compliance with this diet regime was
satisfactory. We chose to study the effect of exercise alone,
not least because it was possible to accurately document
exercise compliance, but also because we have found that
exercise is an attractive behavioural approach to improving
overall lifestyle in this kind of subject group. In addition, an
alteration of diet, in conjunction with exercise, would have
made it more difficult to interpret any changes in
physiological measurements.
In 2005 a group in Canada reported the effects of
exercise training on glucose homeostasis in almost 600
subjects, using a standard IVGTT [30]. While they
observed a mean increase of 10% in insulin sensitivity
after 20 weeks of aerobic training, between-subject varia-
tions in metabolic response to exercise were large, not
unlike our study. In fact, most subjects showed a deterio-
ration in the acute insulin response to glucose. It has been
suggested that progressive resistance training confers
greater metabolic benefits than aerobic training [31, 32].
While the exercise modality may also be relevant, most
studies to date, including our own, have examined the
effects of aerobic exercise training.
In this previously sedentary cohort it is also possible that
our subjects were less active than previously outside the
training times. We did not make any specific measurements
of overall physical activity in the current study and we
think it unlikely that this could have been reduced. While
devices are being developed to measure physical activity
continuously over several days [33], we did not use these in
our study.
More basic physiological and biochemical mechanisms
might explain the non-response to exercise in these patients.
For example, certain diabetes susceptibility genotypes
might predispose individuals to respond or not to respond
to exercise. It is possible that subjects with early-onset type 2
diabetes (and severe obesity) have either genetic or
acquired factors that confer resistance at the level of
skeletal muscle to the expected benefits of aerobic exercise
training. It is now widely recognised that mitochondrial
dysfunction contributes significantly to insulin resistance
and loss of insulin secretion in type 2 diabetes. The failure
to increase VO2max in the diabetes subjects is consistent
with mitochondrial dysfunction, which could result from a
number of causes, including persistent lipotoxicity, which
did not improve in this group after exercise. Further studies
will be required to address these questions, which are so
important for the development of effective treatments for
these high-risk patients.
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